Hyperhomocysteinemia and myocardial expression of brain natriuretic peptide in rats

Clinical Chemistry

Volumn 53, Issue 4, 2007, Pages 773-780

  Herrmann, Markus ^a   Taban Shoma, Omid ^a   Hübner, Ulrich ^a   Pexa, Anette ^b   Kilter, Heiko ^a   Umanskaya, Natalia ^a   Straub, Rainer Hans ^c   Böhm, Michael ^a   Herrmann, Wolfgang ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; HOMOCYSTEINE; HOMOCYSTINE; INTERSTITIAL COLLAGENASE; METHIONINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL INFILTRATION; CONTROLLED STUDY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART VENTRICLE REMODELING; HYPERHOMOCYSTEINEMIA; MAST CELL; MORPHOMETRICS; NONHUMAN; PROTEIN EXPRESSION; RAT;

ANIMALS; FEMALE; HYPERHOMOCYSTEINEMIA; MAST CELLS; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN; ORGAN SIZE; RANDOM ALLOCATION; RATS; RATS, WISTAR; VENTRICULAR REMODELING;

ANIMALIA; RATTUS;

EID: 34147192984     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2006.077859     Document Type: Article

References (38)

1. Vasan RS, Beiser A, D'Agostino RB, Levy D, Selhub J, Jacques PF, et al. Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction. JAMA 2003;289:1251-7.
2. Herrmann W, Quast S, Ullrich M, Schultze H, Bodis M, Geisel J. Hyperhomocysteinemia in high-aged subjects: relation of B-vitamins, folic acid, renal function and the methylenetetrahydrofolate reductase mutation. Atherosclerosis 1999;144:91-101.
3. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, et al. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006;113:e85-151.
4. Cleland JG, Khand A, Clark A. The heart failure epidemic: exactly how big is it? Eur Heart J 2001;22:623-6.
5. Kenchaiah S, Narula J, Vasan RS. Risk factors for heart failure. Med Clin North Am 2004;88:1145-72.
6. Herrmann M, Kindermann I, Muller S, Georg T, Kindermann M, Bohm M, et al. Relationship of plasma homocysteine with the severity of chronic heart failure. Clin Chem 2005;51:1512-5.
7. Kennedy RH, Melchert RB, Joseph J. Cardiovascular effects of hyperhomocysteinemia in conscious unrestrained rats. Am J Hypertens 2006;19:94-7.
8. Ventura P, Panini R, Verlato C, Scarpetta G, Salvioli G. Hyperhomocysteinemia and related factors in 600 hospitalized elderly subjects. Metabolism 2001;50:1466-71.
9. Herrmann M, Mueller S, Kindermann I, Guenther L, Koenig J, Boehm M, et al. Plasma B-vitamins and their relation to the severity of chronic heart failure. Am J Clin Nutr 2007;in print.
10. Cho SE, Sook HK, Shin GJ, Chung WS. The methylenetetrahydrofolate reductase C677T gene mutation is associated with hyperhomocysteinemia, cardiovascular disease and plasma B-type natriuretic peptide concentrations in Korea. Clin Chem Lab Med 2006;44:1070-5.
11. Devi S, Kennedy RH, Joseph L, Shekhawat NS, Melchert RB, Joseph J. Effect of long-term hyperhomocysteinemia on myocardial structure and function in hypertensive rats. Cardiovasc Pathol 2006;15:75-82.
12. Joseph J, Joseph L, Shekhawat NS, Devi S, Wang J, Melchert RB, et al. Hyperhomocysteinemia leads to pathological ventricular hypertrophy in normotensive rats. Am J Physiol Heart Circ Physiol 2003;285:H679-86.
13. Joseph J, Washington A, Joseph L, Kennedy RH. Hyperhomocysteinaemia- induced atrial remodeling in hypertensive rats. Clin Exp Pharmacol Physiol 2004;31:331-7.
14. Joseph J, Washington A, Joseph L, Koehler L, Fink LM, Hauer-Jensen M, et al. Hyperhomocysteinemia leads to adverse cardiac remodeling in hypertensive rats. Am J Physiol Heart Circ Physiol 2002;283:H2567-74.
15. Hobbs FD, Davis RC, Roalfe AK, Hare R, Davies MK. Reliability of N-terminal proBNP assay in diagnosis of left ventricular systolic dysfunction within representative and high risk populations. Heart 2004;90:866-70.
16. Nielsen LS, Svanegaard J, Klitgaard NA, Egeblad H. N-terminal pro-brain natriuretic peptide for discriminating between cardiac and non-cardiac dyspnoea. Eur J Heart Fail 2004;6:63-70.
17. McDonagh TA, Holmer S, Raymond I, Luchner A, Hildebrant P, Dargie HJ. NT-proBNP and the diagnosis of heart failure: a pooled analysis of three European epidemiological studies. Eur J Heart Fail 2004;6:269-73.
18. Yamaguchi H, Yoshida J, Yamamoto K, Sakata Y, Mano T, Akehi N, et al. Elevation of plasma brain natriuretic peptide is a hallmark of diastolic heart failure independent of ventricular hypertrophy. J Am Coll Cardiol 2004;43:55-60.
19. Lubien E, DeMaria A, Krishnaswamy P, Clopton P, Koon J, Kazanegra R, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation 2002;105:595-601.
20. Mueller C, Scholer A, Laule-Kilian K, Martina B, Schindler C, Buser P, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004;350:647-54.
21. Mueller T, Gegenhuber A, Dieplinger B, Poelz W, Haltmayer M. Capability of B-type natriuretic peptide (BNP) and amino-terminal proBNP as indicators of cardiac structural disease in asymptomatic patients with systemic arterial hypertension. Clin Chem 2005;51:2245-51.
22. Hammerer-Lercher A, Ludwig W, Falkensammer G, Muller S, Neubauer E, Puschendorf B, et al. Natriuretic peptides as markers of mild forms of left ventricular dysfunction: effects of assays on diagnostic performance of markers. Clin Chem 2004;50:1174-83.
23. Collinson PO, Barnes SC, Gaze DC, Galasko G, Lahiri A, Senior R. Analytical performance of the N terminal pro B type natriuretic peptide (NT-proBNP) assay on the Elecsys 1010 and 2010 analysers. Eur J Heart Fail 2004;6:365-8.
24. Southern FN, Cruz N, Fink LM, Cooney CA, Barone GW, Eidt JF, et al. Hyperhomocysteinemia increases intimal hyperplasia in a rat carotid endarterectomy model. J Vasc Surg 1998;28:909-18.
25. Junqueira LC, Bignolas G, Brentani RR. Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections. Histochem J 1979;11:447-55.
26. Joseph J, Kennedy RH, Devi S, Wang J, Joseph L, Hauer-Jensen M. Protective role of mast cells in homocysteine-induced cardiac remodeling. Am J Physiol Heart Circ Physiol 2005;288:H2541-45.
27. Roberts IS, Brenchley PE. Mast cells: the forgotten cells of renal fibrosis. J Clin Pathol 2000;53:858-62.
28. Jeron A, Kaiser T, Straub RH, Weil J, Riegger GA, Muders F. Myocardial IL-6 regulation by neurohormones: an in vitro superfusion study. Brain Behav Immun 2003;17:245-50.
29. Durand P, Prost M, Loreau N, Lussier-Cacan S, Blache D. Impaired homocysteine metabolism and atherothrombotic disease. Lab Invest 2001;81:645-72.
30. Stanger O, Herrmann W, Pietrzik K, Fowler B, Geisel J, Dierkes J, et al. DACH-LIGA Homocystein (German, Austrian and Swiss Homocysteine Society): Consensus paper on the rational clinical use of homocysteine, folic acid and B vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations. Clin Chem Lab Med 2003;41:1392-403.
31. Woo CW, Siow YL, O K. Homocysteine activates cAMP-response element binding protein in HepG2 through cAMP/PKA signaling pathway. Arterioscler Thromb Vasc Biol 2006;26:1043-50.
32. Celinski R, Cholewinski W, Stefaniak B, Tarkowska A. Relationship between plasma BNP levels and left ventricular diastolic function as measured by radionuclide ventriculography in patients with coronary artery disease. Nucl Med Rev Cent East Eur 2004;7:123-8.
33. Clerico A, Recchia FA, Passino C, Emdin M. Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications. Am J Physiol Heart Circ Physiol 2006;290:H17-29.
34. Schulze CP, Gielen S, Adams V, Linke A, Möbius-Winkler S, Erbs S, et al. Muscular levels of proinflammatory cytokines correlate with a reduced expression of insulin like growth factor-I in chronic heart failure. Bas Res Cardiol 2006;98:267-74.
35. Rosenkranz AC, Woods RL, Dusting GJ, Ritchie RH. Antihypertrophic actions of the natriuretic peptides in adult rat cardiomyocytes: importance of cyclic GMP. Cardiovasc Res 2003;57:515-22.
36. D'Souza SP, Davis M, Baxter GF. Autocrine and paracrine actions of natriuretic peptides in the heart. Pharmacol Ther 2004;101:113-29.
37. Zaina S, Lindholm MW, Lund G. Nutrition and aberrant DNA methylation patterns in atherosclerosis: more than just hyperhomocysteinemia? J Nutr 2005;135:5-8.
38. James SJ, Melnyk S, Pogribna M, Pogribny IP, Caudill MA. Elevation in S-adenosylhomocysteine and DNA hypomethylation: potential epigenetic mechanism for homocysteine-related pathology. J Nutr 2002;132(Suppl 8):2361S-6S.